| 1. |
Russell, D. W. and Miller, A. D. (1996) Foamy viras vectors. J. Virol.
70, 217–222.
|
| |
| 2. |
Perkins, A. S., Kirschmeier, P. T., Gattoni-Celli, S., and Weinstein, I. B. (1983) Design of a retrovirus-derived vector for
expression and transduction of exogenous genes in mammalian cells. Mol. Cell. Biol.
3, 1123–1132.
|
| |
| 3. |
Girod, A., Cosset, F. L., Verdier, G., and Ronfort, C. (1995) Analysis of ALV-based packaging cell lines for production of
contaminant defective viruses. Virology
209, 671–675.
|
| |
| 4. |
Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996) Efficient transfer, integration, and sustained longterm
expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA
93, 11,382–11,388.
|
| |
| 5. |
Poeschla, E., Gilbert, J., Li, X., Huang, S., Ho, A., and Wong-Staal, F (1998) Identification of a human immunodeficiency
virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors.
J. Virol.
72, 6527–6536.
|
| |
| 6. |
Mangeot, P. E., Negre, D., Dubois, B., et al. (2000) Development of minimal lentivirus vectors derived from simian immunodeficiency
virus (SIVmac251) and their use for gene transfer into human dendritic cells. J. Virol.
74, 8307–8315.
|
| |
| 7. |
Poeschla, E. M., Wong-Staal, F, and Looney, D. J. (1998) Efficient transduction of nondividing human cells by feline immunodeficiency
virus lentiviral vectors. Nat. Med.
4, 354–357.
|
| |
| 8. |
Matukonis, M., Li, M., Molina, R. P., Paszkiet, B., Kaleko, M., and Luo, T. (2002) Development of second-and third-generation
bovine immunodeficiency virus-based gene transfer systems. Hum. Gene Ther.
13, 1293–1303.
|
| |
| 9. |
Mitrophanous, K., Yoon, S., Rohll, J., et al. (1999) Stable gene transfer to the nervous system using a non-primate lentiviral
vector. Gene Ther.
6, 1808–1818.
|
| |
| 10. |
Mselli-Lakhal, L., Favier, C., Da Silva Teixeira, M. F., et al. (1998) Defective RNA packaging is responsible for low transduction
efficiency of CAEV-based vectors. Arch. Virol.
143, 681–695.
|
| |
| 11. |
Metharom, P., Takyar, S., Xia, H. H., et al. (2000) Novel bovine lentiviral vectors based on Jembrana disease virus. J. Gene Med.
2, 176–185.
|
| |
| 12. |
Savard, N., Cosset, F. L., and Epstein, A. L. (1997) Defective herpes simplex virus type 1 vectors harboring gag, pol, and
env genes can be used to rescue defective retrovirus vectors. J. Virol.
71, 4111–4117.
|
| |
| 13. |
Sena-Esteves, M., Saeki, Y., Camp, S. M., Chiocca, E. A., and Breakefield, X. O. (1999) Single-step conversion of cells to
retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J. Virol.
73, 10,426–10,439.
|
| |
| 14. |
Li, K. J. and Garoff, H. (1996) Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells
using Semliki Forest virus-derived RNA expression vectors. Proc. Natl. Acad. Sci. USA
93, 11,658–11,663.
|
| |
| 15. |
Li, K. J. and Garoff, H. (1998) Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc. Natl. Acad. Sci. USA
95, 3650–3654.
|
| |
| 16. |
Wahlfors, J. J. and Morgan, R. A. (1999) Production of minigene-containing retroviral vectors using an alphavirus/retrovirus
hybrid vector system. Hum. Gene Ther.
10, 1197–1206.
|
| |
| 17. |
Wahlfors, J. J., Xanthopoulos, K. G., and Morgan, R. A. (1997) Semliki Forest virus-mediated production of retroviral vector
RNA in retroviral packaging cells. Hum. Gene Ther.
8, 2031–2041.
|
| |
| 18. |
Bilbao, G., Feng, M., Rancourt, C., Jackson, W. H., Jr., and Curiel, D. T. (1997) Adenoviral/retroviral vector chimeras: a
novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J.
11, 624–634.
|
| |
| 19. |
Caplen, N. J., Higginbotham, J. N., Scheel, J. R., et al. (1999) Adeno-retroviral chimeric viruses as in vivo transducing
agents. Gene Ther.
6, 454–459.
|
| |
| 20. |
Feng, M., Jackson, W. H., Jr., Goldman, C. K., et al. (1997) Stable in vivo gene transduction via a novel adenoviral/retroviral
chimeric vector. Nat. Biotechnol.
15, 866–870.
|
| |
| 21. |
Lin, X. (1998) Construction of new retroviral producer cells from adenoviral and retroviral vectors. Gene Ther.
5, 1251–1258.
|
| |
| 22. |
Ramsey, W. J., Caplen, N. J., Li, Q., Higginbotham, J. N., Shah, M., and Blaese, R. M. (1998) Adenovirus vectors as transcomplementing
templates for the production of replication defective retroviral vectors. Biochem. Biophys. Res. Commun.
246, 912–919.
|
| |
| 23. |
Yoshida, Y., Emi, N., and Hamada, H. (1997) VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene
expression. Biochem. Biophys. Res. Commun.
232, 379–382.
|
| |
| 24. |
Kuate, S., Stefanou, D., Hoffmann, D., Wildner, O., and Uberla, K. (2004) Production of lentiviral vectors by transient expression
of minimal packaging genes from recombinant adenoviruses. J. Gene Med.
6, 1197–1205.
|
| |
| 25. |
Kubo, S. and Mitani, K. (2003) A new hybrid system capable of efficient lentiviral vector production and stable gene transfer
mediated by a single helper-dependent adenoviral vector. J. Virol.
77, 2964–2971.
|
| |
| 26. |
Doerfler, W. and Boehm, P. (1995) The Molecular Repertoire of Adenoviruses, Springer, Berlin.
|
| |
| 27. |
Stewart, P. L. (2002) Adenovirus Structure, Academic Press, San Diego, CA.
|
| |
| 28. |
Roelvink, P. W., Lizonova, A., Lee, J. G., et al. (1998) The coxsackievirus-adenovirus receptor protein can function as a
cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol.
72, 7909–7915.
|
| |
| 29. |
Bergelson, J. M., Cunningham, J. A., Droguett, G., et al. (1997) Isolation of a common receptor for coxsackie B viruses and
adenoviruses 2 and 5. Science
275, 1320–1323.
|
| |
| 30. |
Tomko, R. P., Xu, R., and Philipson, L. (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses
and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA
94, 3352–3356.
|
| |
| 31. |
Wickham, T. J., Mathias, P., Cheresh, D. A., and Nemerow, G. R. (1993) Integrins alpha v beta 3 and alpha v beta 5 promote
adenovirus internalization but not virus attachment. Cell
73, 309–319.
|
| |
| 32. |
Li, E., Brown, S. L., Stupack, D. G., Puente, X. S., Cheresh, D. A., and Nemerow, G. R. (2001) Integrin v 1 is an adenovirus
coreceptor. J. Virol.
75, 5405–5409.
|
| |
| 33. |
Meier, O. and Greber, U. F. (2004) Adenovirus endocytosis. J. Gene Med.
6(Suppl 1), S152–S163.
|
| |
| 34. |
Shenk, T. (1996) The Viruses and Their Replication, Lippincott, Philadelphia: Lippincott.
|
| |
| 35. |
Imler, J. L., Bout, A., Dreyer, D., et al. (1995) Trans-complementation of E1-deleted adenovirus: a new vector to reduce the
possibility of codissemination of wild-type and recombinant adenoviruses. Hum. Gene Ther.
6, 711–721.
|
| |
| 36. |
Doerfler, W. and Boehm, P. (1995) The Molecular Repertoire of Adenoviruses, Berlin, Springer.
|
| |
| 37. |
Breyer, B., Jiang, W., Cheng, H., et al. (2001) Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther.
1, 149–162.
|
| |
| 38. |
Chuah, M. K., Collen, D., and VandenDriessche, T. (2003) Biosafety of adenoviral vectors. Curr. Gene Ther.
3, 527–543.
|
| |
| 39. |
Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from
human adenovirus type 5. J. Gen. Virol.
36, 59–74.
|
| |
| 40. |
Nadeau, I. and Kamen, A. (2003) Production of adenovirus vector for gene therapy. Biotechnol. Adv.
20, 475–489.
|
| |
| 41. |
Gamier, A., Cote, J., Nadeau, I., Kamen, A., and Massie, B. (1994) Scale-up of the adenovirus expression system for the production
of recombinant protein in human 293S cells. Cytotechnology
15, 145–155.
|
| |
| 42. |
Cote, J., Gamier, A., Massie, B., and Kamen, A. (1998) Serum-free production of recombinant proteins and adenoviral vectors
by 293SF-3F6 cells. Biotechnol. Bioeng.
59, 567–575.
|
| |
| 43. |
Peshwa, M. V., Kyung, Y. S., McClure, D. B., and Hu, W. S. (1993) Cultivation of mammalian cells as aggregates in bioreactors:
effect of calcium concentration of spatial distribution of viability. Biotechnol. Bioeng.
41, 179–187.
|
| |
| 44. |
Lochmuller, H., Jani, A., Huard, J., et al. (1994) Emergence of early region 1-containing replication-competent adenovirus
in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum. Gene Ther.
5, 1485–1491.
|
| |
| 45. |
Fallaux, F. J., Kranenburg, O., Cramer, S. J., et al. (1996) Characterization of 911: a new helper cell line for the titration
and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther.
7, 215–222.
|
| |
| 46. |
Schiedner, G., Hertel, S., and Kochanek, S. (2000) Efficient transformation of primary human amniocytes by E1 functions of
Ad5: generation of new cell lines for adenoviral vector production. Hum. Gene Ther.
11, 2105–2116.
|
| |
| 47. |
Fallaux, F. J., Bout, A., van der Velde, I., et al. (1998) New helper cells and matched early region 1-deleted adenovirus
vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther.
9, 1909–1917.
|
| |
| 48. |
Imler, J. L., Chartier, C., Dreyer, D., et al. (1996) Novel complementation cell lines derived from human lung carcinoma A549
cells support the growth of El-deleted adenovirus vectors. Gene Ther.
3, 75–84.
|
| |
| 49. |
Gao, G., Qu, G., Burnham, M. S., et al. (2000) Purification of recombinant adeno-associated virus vectors by column chromatography
and its performance in vivo. Hum. Gene Ther.
11, 2079–2091.
|
| |
| 50. |
Volpers, C. and Kochanek, S. (2004) Adenoviral vectors for gene transfer and therapy. J. Gene Med.
6(Suppl 1), S164–S171.
|
| |
| 51. |
Amalfitano, A., Hauser, M. A., Hu, H., Serra, D., Begy, C. R., and Chamberlain, J. S. (1998) Production and characterization
of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol.
72, 926–933.
|
| |
| 52. |
Armentano, D., Zabner, J., Sacks, C., et al. (1997) Effect of the E4 region on the persistence of transgene expression from
adenovirus vectors. J. Virol.
71, 2408–2416.
|
| |
| 53. |
Alba, R., Bosch, A., and Chillon, M. (2005) Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther.
12(Suppl 1), S18–S27.
|
| |
| 54. |
Wu, S. C., Huang, G. Y., and Liu, J. H. (2002) Production of retrovirus and adenovirus vectors for gene therapy: a comparative
study using microcarrier and stationary cell culture. Biotechnol. Prog.
18, 617–622.
|
| |
| 55. |
Iyer, P., Ostrove, J. M., and Vacante, D. (1999) Comparison of manufacturing techniques for adenovirus production. Cytotechnology
30, 169–172.
|
| |
| 56. |
Kamen, A. and Henry, O. (2004) Development and optimization of an adenovirus production process. J. Gene Med.
6(Suppl 1), S184–S192.
|
| |
| 57. |
Nadeau, I., Gamier, A., Côté, J., Massie, B., Chavarie, C., and Kamen, A. (1996) Improvement of recombinant protein production
with the human adenovirus/293 S expression system using fed-batch strategies. Biotechnol. Bioeng.
51, 613–623.
|
| |
| 58. |
Yuk, I. H., Olsen, M. M., Geyer, S., and Forestell, S. P. (2004) Perfusion cultures of human tumor cells: a scalable production
platform for oncolytic adenoviral vectors. Biotechnol. Bioeng.
86, 637–642.
|
| |
| 59. |
Warnock, J. N., Merten, O. W., and Al-Rubeai, M. (2006) Cell culture processes for the production of viral vectors for gene
therapy purposes. Cytotechnology
50, 141–162.
|
| |
| 60. |
Burova, E. and Ioffe, E. (2005) Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors:
methods and implications. Gene Ther.
12(Suppl 1), S5–S17.
|
| |
| 61. |
Duffy, A. M., O’Doherty, A. M., O’Brien, T., and Strappe, P. M. (2005) Purification of adenovirus and adeno-associated virus:
comparison of novel membrane-based technology to conventional techniques. Gene Ther.
12(Suppl 1), S62–S72.
|
| |
| 62. |
Maizel, J. V., Jr., White, D. O., and Scharff, M. D. (1968) The polypeptides of adenovirus. I. Evidence for multiple protein
components in the virion and a comparison of types 2, 7A, and 12. Virology
36, 115–125.
|
| |
| 63. |
Shabram, P. W., Giroux, D. D., Goudreau, A. M., et al. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral
particles. Hum. Gene Ther.
8, 453–465.
|
| |
| 64. |
Nyberg-Hoffman, C., Shabram, P., Li, W., Giroux, D., and Aguilar-Cordova, E. (1997) Sensitivity and reproducibility in adenoviral
infectious titer determination. Nat. Med.
3, 808–811.
|
| |
| 65. |
Mittereder, N., March, K. L., and Trapnell, B. C. (1996) Evaluation of the concentration and bioactivity of adenovirus vectors
for gene therapy. J. Virol.
70, 7498–7509.
|
| |
| 66. |
Lusky, M., Christ, M., Rittner, K., et al. (1998) In vitro and in vivo biology of recombinant adenovirus vectors with E1,
E1/E2A, or E1/E4 deleted. J. Virol.
72, 2022–2032.
|
| |
| 67. |
Zabner, J., Chillon, M., Grunst, T., et al. (1999) A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene
transfer to human airway epithelia. J. Virol.
73, 8689–8695.
|
| |
| 68. |
Hutchins, B. (2002) Development of a reference material for characterization adenovirus vector. Bioproc. J.
1, 25–28.
|
| |
| 69. |
Gao, F. G., Jeevarajan, A. S., and Anderson, M. M. (2004) Long-term continuous monitoring of dissolved oxygen in cell culture
medium for perfused bioreactors using optical oxygen sensors. Biotechnol. Bioeng.
86, 425–433.
|
| |
| 70. |
Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J. M. (2002) Novel adeno-associated viruses from
rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA
99, 11,854–11,859.
|
| |
| 71. |
Mori, S., Wang, L., Takeuchi, T., and Kanda, T. (2004) Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping
characterization of capsid protein. Virology
330, 375–383.
|
| |
| 72. |
Rutledge, E. A., Halbert, C. L., and Russell, D. W. (1998) Infectious clones and vectors derived from adeno-associated virus
(AAV) serotypes other than AAV type 2. J. Virol.
72, 309–319.
|
| |
| 73. |
Gao, G., Vandenberghe, L. H., and Wilson, J. M. (2005) New recombinant serotypes of AAV vectors. Curr. Gene Ther.
5, 285–297.
|
| |
| 74. |
Qiu, J. and Pintel, D. J. (2004) Alternative polyadenylation of adeno-associated virus type 5 RNA within an internal intron
is governed by the distance between the promoter and the intron and is inhibited by U1 small nuclear RNP binding to the intervening
donor. J. Biol. Chem.
279, 14,889–14,898.
|
| |
| 75. |
Erles, K., Sebokova, P., and Schlehofer, J. R. (1999) Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated
virus (AAV). J. Med. Virol.
59, 406–411.
|
| |
| 76. |
Tobiasch, E., Burguete, T., Klein-Bauernschmitt, P., Heilbronn, R., and Schlehofer, J. R. (1998) Discrimination between different
types of human adeno-associated viruses in clinical samples by PCR. J. Virol. Methods
71, 17–25.
|
| |
| 77. |
Kotin, R. M., Siniscalco, M., Samulski, R. J., et al. (1990) Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA
87, 2211–2215.
|
| |
| 78. |
Samulski, R. J., Zhu, X., Xiao, X., et al. (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome
19. EMBO J.
10, 3941–3950.
|
| |
| 79. |
Shelling, A. N. and Smith, M. G. (1994) Targeted integration of transfected and infected adeno-associated virus vectors containing
the neomycin resistance gene. Gene Ther.
1, 165–169.
|
| |
| 80. |
Grimm, D. and Kay, M. A. (2003) From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated
virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther.
3, 281–304.
|
| |
| 81. |
Srivastava, A., Lusby, E. W., and Berns, K. I. (1983) Nucleotide sequence and organization of the adeno-associated virus 2
genome. J. Virol.
45, 555–564.
|
| |
| 82. |
Tratschin, J. D., Miller, I. L., and Carter, B. J. (1984) Genetic analysis of adeno-associated virus: properties of deletion
mutants constructed in vitro and evidence for an adeno-associated virus replication function. J. Virol.
51, 611–619.
|
| |
| 83. |
Weitzman, M. D., Kyostio, S. R., Kotin, R. M., and Owens, R. A. (1994) Adeno-associated virus (AAV) Rep proteins mediate complex
formation between AAV DNA and its integration site in human DNA. Proc. Natl. Acad. Sci. USA
91, 5808–5812.
|
| |
| 84. |
Horer, M., Weger, S., Butz, K., Hoppe-Seyler, F., Geisen, C., and Kleinschmidt, J. A. (1995) Mutational analysis of adeno-associated
virus Rep protein-mediated inhibition of heterologous and homologous promoters. J. Virol.
69, 5485–5496.
|
| |
| 85. |
Pereira, D. J., McCarty, D. M., and Muzyczka, N. (1997) The adeno-associated virus (AAV) Rep protein acts as both a repressor
and an activator to regulate AAV transcription during a productive infection. J. Virol.
71, 1079–1088.
|
| |
| 86. |
King, J. A., Dubielzig, R., Grimm, D., and Kleinschmidt, J. A. (2001) DNA helicase-mediated packaging of adeno-associated
virus type 2 genomes into preformed capsids. EMBO J.
20, 3282–3291.
|
| |
| 87. |
Timpe, J., Bevington, J., Casper, J., Dignam, J. D., and Trempe, J. P. (2005) Mechanisms of adeno-associated virus genome
encapsidation. Curr. Gene Ther.
5, 273–284.
|
| |
| 88. |
Schlehofer, J. R., Ehrbar, M., and zur Hausen, H. (1986) Vaccinia virus, herpes simplex virus, and carcinogens induce DNA
amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology
152, 110–117.
|
| |
| 89. |
Weindler, F. W. and Heilbronn, R. (1991) A subset of herpes simplex virus replication genes provides helper functions for
productive adeno-associated virus replication. J. Virol.
65, 2476–2483.
|
| |
| 90. |
McPherson, R. A., Rosenthal, L. J., and Rose, J. A. (1985) Human cytomegalovirus completely helps adeno-associated virus replication.
Virology
147, 217–222.
|
| |
| 91. |
Chon, S. K., Rim, B. M., and Im, D. S. (1999) Adeno-associated viras Rep78 binds to E2-responsive element 1 of bovine papillomavirus
type 1. IUBMB Life
48, 397–404.
|
| |
| 92. |
Geoffroy, M. C. and Salvetti, A. (2005) Helper functions required for wild type and recombinant adeno-associated virus growth.
Curr. Gene Ther.
5, 265–271.
|
| |
| 93. |
Wistuba, A., Kern, A., Weger, S., Grimm, D., and Kleinschmidt, J. A. (1997) Subcellular compartmentalization of adeno-associated
virus type 2 assembly. J. Virol.
71, 1341–1352.
|
| |
| 94. |
Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. A. (1998) Novel tools for production and purification of recombinant
adenoassociated virus vectors. Hum. Gene Ther.
9, 2745–2760.
|
| |
| 95. |
Xiao, X., Li, J., and Samulski, R. J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence
of helper adenovirus. J. Virol.
72, 2224–2232.
|
| |
| 96. |
Chiorini, J. A., Kim, F., Yang, L., and Kotin, R. M. (1999) Cloning and characterization of adeno-associated virus type 5.
J. Virol.
73, 1309–1319.
|
| |
| 97. |
Chiorini, J. A., Yang, L., Liu, Y., Safer, B., and Kotin, R. M. (1997) Cloning of adeno-associated virus type 4 (AAV4) and
generation of recombinant AAV4 particles. J. Virol.
71, 6823–6833.
|
| |
| 98. |
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., and Wilson, J. M. (1999) Gene therapy vectors based on adeno-associated
virus type 1. J. Virol.
73, 3994–4003.
|
| |
| 99. |
Brown, P., Barret, S., Godwin, S., et al. (1998) Optimization of production of adeno-associated virus (AAV) for use in gene
therapy. Presented at Cell Culture Engineering VI, San Diego, CA.
|
| |
| 100. |
Clark, K. R. (2002) Recent advances in recombinant adeno-associated virus vector production. Kidney Int.
61(Suppl 1), S9–S15.
|
| |
| 101. |
Merten, O. W., Geny-Fiamma, C., and Douar, A. M. (2005) Current issues in adeno-associated viral vector production. Gene Ther.
12(Suppl 1), S51–S61.
|
| |
| 102. |
Urabe, M., Ding, C., and Kotin, R. M. (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther.
13, 1935–1943.
|
| |
| 103. |
Meghrous, J., Aucoin, M. G., Jacob, D., Chahal, P. S., Arcand, N., and Kamen, A. A. (2005) Production of recombinant adeno-associated
viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol. Prog.
21, 154–160.
|
| |
| 104. |
Urabe, M., Nakakura, T., Xin, K. Q., et al. (2006) Scalable generation of high-titer recombinant adeno-associated virus type
5 in insect cells. J. Virol.
80, 1874–1885.
|
| |
| 105. |
Kohlbrenner, E., Aslanidi, G., Nash, K., et al. (2005) Successful production of pseudotyped rAAV vectors using a modified
baculovirus expression system. Mol. Ther.
12, 1217–1225.
|
| |
| 106. |
Tenenbaum, L., Hamdane, M., Pouzet, M., et al. (1999) Cellular contaminants of adeno-associated virus vector stocks can enhance
transduction. Gene Ther.
6, 1045–1053.
|
| |
| 107. |
Zolotukhin, S., Byrne, B. J., Mason, E., et al. (1999) Recombinant adeno-associated virus purification using novel methods
improves infectious titer and yield. Gene Ther.
6, 973–985.
|
| |
| 108. |
Blouin, V., Brument, N., Toublanc, E., Raimbaud, I., Moullier, P., and Salvetti, A. (2004) Improving rAAV production and purification:
towards the definition of a scaleable process. J. Gene Med.
6(Suppl 1), S223–S228.
|
| |
| 109. |
Brument, N., Morenweiser, R., Blouin, V., et al. (2002) A versatile and scalable two-step ion-exchange chromatography process
for the purification of recombinant adeno-associated virus serotypes-2 and-5. Mol. Ther.
6, 678–686.
|
| |
| 110. |
Kaludov, N., Handelman, B., and Chiorini, J. A. (2002) Scalable purification of adeno-associated virus type 2, 4, or 5 using
ion-exchange chromatography. Hum. Gene Ther.
13, 1235–1243.
|
| |
| 111. |
Zolotukhin, S., Potter, M., Zolotukhin, I., et al. (2002) Production and purification of serotype 1, 2, and 5 recombinant
adeno-associated viral vectors. Methods
28, 158–167.
|
| |
| 112. |
Flotte, T. R., Solow, R., Owens, R. A., Afione, S., Zeitlin, P. L., and Carter, B. J. (1992) Gene expression from adeno-associated
virus vectors in airway epithelial cells. Am. J. Respir. Cell Mol. Biol.
7, 349–356.
|
| |
| 113. |
Rohr, U. P., Wulf, M. A., Stahn, S., Steidl, U., Haas, R., and Kronenwett, R. (2002) Fast and reliable titration of recombinant
adeno-associated virus type-2 using quantitative real-time PCR. J. Virol. Methods
106, 81–88.
|
| |
| 114. |
Veldwijk, M. R., Topaly, J., Laufs, S., et al. (2002) Development and optimization of a real-time quantitative PCR-based method
for the titration of AAV-2 vector stocks. Mol. Ther.
6, 272.
|
| |
| 115. |
Salvetti, A., Oreve, S., Chadeuf, G., et al. (1998) Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther.
9, 695–706.
|
| |
| 116. |
Farson, D., Harding, T. C., Tao, L., et al. (2004) Development and characterization of a cell line for large-scale, serum-free
production of recombinant adeno-associated viral vectors. J. Gene Med.
6, 1369–1381.
|
| |
| 117. |
Rohr, U. P., Heyd, F., Neukirchen, J., et al. (2005) Quantitative real-time PCR for titration of infectious recombinant AAV-2
particles. J. Virol. Methods
127, 40–45.
|
| |
| 118. |
Otto, E., Jones-Trower, A., Vanin, E. F., et al. (1994) Characterization of a replication-competent retrovirus resulting from
recombination of packaging and vector sequences. Hum. Gene Ther.
5, 567–575.
|
| |
| 119. |
Landau, N. R., and Littman, D. R. (1992) Packaging system for rapid production of murine leukemia virus vectors with variable
tropism. J. Virol.
66, 5110–5113.
|
| |
| 120. |
Yang, S., Delgado, R., King, S. R., et al. (1999) Generation of retroviral vector for clinical studies using transient transfection.
Hum. Gene Ther.
10, 123–132.
|
| |
| 121. |
Barbanti-Brodano, G., Sabbioni, S., Martini, F., Negrini, M., Corallini, A., and Tognon, M. (2004) Simian virus 40 infection
in humans and association with human diseases: results and hypotheses. Virology
318, 1–9.
|
| |
| 122. |
Manilla, P., Rebello, T., Afable, C., et al. (2005) Regulatory considerations for novel gene therapy products: a review of
the process leading to the first clinical lentiviral vector. Hum. Gene Ther.
16, 17–25.
|
| |
| 123. |
Takeuchi, Y., Porter, C. D., Strahan, K. M., et al. (1996) Sensitization of cells and retroviruses to human serum by (alpha
1-3) galactosyltransferase. Nature
379, 85–88.
|
| |
| 124. |
Welsh, R. M., O’Donnell, C. L., Reed, D. J., and Rother, R. P. (1998) Evaluation of the Galalpha1-3Gal epitope as a host modification
factor eliciting natural humoral immunity to enveloped viruses. J. Virol.
72, 4650–4656.
|
| |
| 125. |
Chang, L. J., Urlacher, V., Iwakuma, T., Cui, Y., and Zucali, J. (1999) Efficacy and safety analyses of a recombinant human
immunodeficiency virus type 1 derived vector system. Gene Ther.
6, 715–728.
|
| |
| 126. |
Higashikawa, F., and Chang, L. (2001) Kinetic analyses of stability of simple and complex retroviral vectors. Virology
280, 124–131.
|
| |
| 127. |
Iwakuma, T., Cui, Y., and Chang, L. J. (1999) Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology
261, 120–132.
|
| |
| 128. |
Karolewski, B. A., Watson, D. J., Parente, M. K., and Wolfe, J. H. (2003) Comparison of transfection conditions for a lentivirus
vector produced in large volumes. Hum. Gene Ther.
14, 1287–1296.
|
| |
| 129. |
Mitta, B., Rimann, M., and Fussenegger, M. (2005) Detailed design and comparative analysis of protocols for optimized production
of high-performance HIV-1-derived lentiviral particles. Metab. Eng.
7, 426–436.
|
| |
| 130. |
Nakajima, T., Nakamaru, K., Ido, E., Terao, K., Hayami, M., and Hasegawa, M. (2000) Development of novel simian immunodeficiency
virus vectors carrying a dual gene expression system. Hum. Gene Ther.
11, 1863–1874.
|
| |
| 131. |
Geraerts, M., Michiels, M., Baekelandt, V., Debyser, Z., and Gijsbers, R. (2005) Upscaling of lentiviral vector production
by tangential flow filtration. J. Gene Med.
7, 1299–1310.
|
| |
| 132. |
Coleman, J. E., Huentelman, M. J., Kasparov, S., et al. (2003) Efficient large-scale production and concentration of HIV-1-based
lentiviral vectors for use in vivo. Physiol. Genomics
12, 221–228.
|
| |
| 133. |
Miller, A. D. and Buttimore, C. (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper
virus production. Mol. Cell. Biol.
6, 2895–2902.
|
| |
| 134. |
Danos, O. and Mulligan, R. C. (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic
host ranges. Proc. Natl. Acad. Sci. USA
85, 6460–6464.
|
| |
| 135. |
Markowitz, D., Goff, S., and Bank, A. (1988) Construction and use of a safe and efficient amphotropic packaging cell line.
Virology
167, 400–406.
|
| |
| 136. |
Markowitz, D., Hesdorffer, C., Ward, M., Goff, S., and Bank, A. (1990) Retroviral gene transfer using safe and efficient packaging
cell lines. Ann. NY Acad. Sci.
612, 407–414.
|
| |
| 137. |
Morgenstern, J. P. and Land, H. (1990) Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug
selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res.
18, 3587–3596.
|
| |
| 138. |
Kaul, M., Yu, H., Ron, Y., and Dougherty, J. P. (1998) Regulated lentiviral packaging cell line devoid of most viral cis-acting
sequences. Virology
249, 167–174.
|
| |
| 139. |
Yu, H., Rabson, A. B., Kaul, M., Ron, Y., and Dougherty, J. P. (1996) Inducible human immunodeficiency virus type 1 packaging
cell lines. J. Virol.
70, 4530–4537.
|
| |
| 140. |
Farson, D., Witt, R., McGuinness, R., et al. (2001) A new-generation stable inducible packaging cell line for lentiviral vectors.
Hum. Gene Ther.
12, 981–997.
|
| |
| 141. |
Kafri, T., van Praag, H., Ouyang, L., Gage, F. H., and Verma, I. M. (1999) A packaging cell line for lentivirus vectors. J. Virol.
73, 576–584.
|
| |
| 142. |
Klages, N., Zufferey, R., and Trono, D. (2000) A stable system for the high-titer production of multiply attenuated lentiviral
vectors. Mol. Ther.
2, 170–176.
|
| |
| 143. |
Scherr, M., Battmer, K., Schultheis, B., Ganser, A., and Eder, M. (2005) Stable RNA interference (RNAi) as an option for anti-bcr-abl
therapy. Gene Ther.
12, 12–21.
|
| |
| 144. |
Xu, K., Ma, H., McCown, T. J., Verma, I. M., and Kafri, T. (2001) Generation of a stable cell line producing high-titer self-inactivating
lentiviral vectors. Mol. Ther.
3, 97–104.
|
| |
| 145. |
Pacchia, A. L., Adelson, M. E., Kaul, M., Ron, Y., and Dougherty, J. P. (2001) An inducible packaging cell system for safe,
efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology
282, 77–86.
|
| |
| 146. |
Sparacio, S., Pfeiffer, T., Schaal, H., and Bosch, V. (2001) Generation of a flexible cell line with regulatable, high-level
expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther.
3, 602–612.
|
| |
| 147. |
Kuate, S., Wagner, R., and Uberla, K. (2002) Development and characterization of a minimal inducible packaging cell line for
simian immunodeficiency virus-based lentiviral vectors. J. Gene Med.
4, 347–355.
|
| |
| 148. |
Spaete, R. R. and Frenkel, N. (1982) The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying
vector. Cell
30, 295–304.
|
| |
| 149. |
Johnston, K. M., Jacoby, D., Pechan, P. A., et al. (1997) HSV/AAV hybrid amplicon vectors extend transgene expression in human
glioma cells. Hum. Gene Ther.
8, 359–370.
|
| |
| 150. |
Wang, S. and Vos, J. M. (1996) A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus
type 1 for gene transfer into human cells in vitro and in vivo. J. Virol.
70, 8422–8430.
|
| |
| 151. |
Lu, X., Humeau, L., Slepushkin, V, et al. (2004) Safe two-plasmid production for the first clinical lentivirus vector that
achieves >99% transduction in primary cells using a one-step protocol. J. Gene Med.
6, 963–973.
|
| |
| 152. |
Przybylowski, M., Hakakha, A., Stefanski, J., Hodges, J., Sadelain, M., and Riviere, I. (2005) Production scale-up and validation
of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Ther.
13, 95–100.
|
| |
| 153. |
Reiser, J. (2000) Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther.
7, 910–913.
|
| |
| 154. |
Steffens, S., Tebbets, J., Kramm, C. M., Lindemann, D., Flake, A., and Sena-Esteves, M. (2004) Transduction of human glial
and neuronal tumor cells with different lentivirus vector pseudotypes. J. Neurooncol.
70, 281–288.
|
| |
| 155. |
Martin-Rendon, E., White, L. J., Olsen, A., Mitrophanous, K. A., and Mazarakis, N. D. (2002) New methods to titrate EIAV-based
lentiviral vectors. Mol. Ther.
5, 566–570.
|
| |
| 156. |
Goff, S., Traktman, P., and Baltimore, D. (1981) Isolation and properties of Moloney murine leukemia virus mutants: use of
a rapid assay for release of virion reverse transcriptase. J. Virol.
38, 239–248.
|
| |
| 157. |
Eberle, J. and Seibl, R. (1992) A new method for measuring reverse transcriptase activity by ELISA. J. Virol. Methods
40, 347–356.
|
| |
| 158. |
Pyra, H., Boni, J., and Schupbach, J. (1994) Ultrasensitive retrovirus detection by a reverse transcriptase assay based on
product enhancement. Proc. Natl. Acad. Sci. USA
91, 1544–1548.
|
| |
| 159. |
Arnold, B. A., Hepler, R. W., and Keller, P. M. (1998) One-step fluorescent probe product-enhanced reverse transcriptase assay.
Biotechniques
25, 98–106.
|
| |
| 160. |
Ikeda, Y., Collins, M. K., Radcliffe, P. A., Mitrophanous, K. A., and Takeuchi, Y. (2002) Gene transduction efficiency in
cells of different species by HIV and EIAV vectors. Gene Ther.
9, 932–938.
|
| |
| 161. |
Lizee, G., Aerts, J. L., Gonzales, M. I., Chinnasamy, N., Morgan, R. A., and Topalian, S. L. (2003) Real-time quantitative
reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene
expression. Hum. Gene Ther.
14, 497–507.
|
| |
| 162. |
Sastry, L., Johnson, T., Hobson, M. J., Smucker, B., and Cornetta, K. (2002) Titering lentiviral vectors: comparison of DNA,
RNA and marker expression methods. Gene Ther.
9, 1155–1162.
|
| |
| 163. |
Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F. L., Mitrophanous, K., and Collins, M. (2003) Continuous high-titer HIV-1 vector
production. Nat. Biotechnol.
21, 569–572.
|
| |
| 164. |
Duisit, G., Salvetti, A., Moullier, P., and Cosset, F. L. (1999) Functional characterization of adenoviral/retroviral chimeric
vectors and their use for efficient screening of retroviral producer cell lines. Hum. Gene Ther.
10, 189–200.
|
| |
| 165. |
Coecke, S., Balls, M., Bowe, G., et al. (2005) Guidance on good cell culture practice. A report of the second ECVAM task force
on good cell culture practice. Altern. Lab. Anim.
33, 261–287.
|
| |
| 166. |
Gasmi, M., Glynn, J., Jin, M. J., Jolly, D. J., Yee, J. K., and Chen, S. T. (1999) Requirements for efficient production and
transduction of human immunodeficiency virus type 1-based vectors. J. Virol.
73, 1828–1834.
|
| |
| 167. |
Sakoda, T., Kasahara, N., Hamamori, Y., and Kedes, L. (1999) A high-titer lentiviral production system mediates efficient
transduction of differentiated cells including beating cardiac myocytes. J. Mol. Cell Cardiol.
31, 2037–2047.
|
| |
| 168. |
Sena-Esteves, M., Tebbets, J. C., Steffens, S., Crombleholme, T., and Flake, A. W. (2004) Optimized large-scale production
of high titer lentivirus vector pseudotypes. J. Virol. Methods
122, 131–139.
|
| |
| 169. |
Aloia, R. C., Jensen, F. C., Curtain, C. C., Mobley, P. W., and Gordon, L. M. (1988) Lipid composition and fluidity of the
human immunodeficiency virus. Proc. Natl. Acad. Sci. USA
85, 900–904.
|
| |
| 170. |
Beer, C., Meyer, A., Muller, K., and Wirth, M. (2003) The temperature stability of mouse retroviruses depends on the cholesterol
levels of viral lipid shell and cellular plasma membrane. Virology
308, 137–146.
|
| |
| 171. |
Zhang, B., Xia, H. Q., Cleghorn, G., Gobe, G., West, M., and Wei, M. Q. (2001) A highly efficient and consistent method for
harvesting large volumes of high-titer lentiviral vectors. Gene Ther.
8, 1745–1751.
|
| |
| 172. |
Pham, L., Ye, H., Cosset, F. L., Russell, S. I., and Peng, K. W. (2001) Concentration of viral vectors by co-precipitation
with calcium phosphate. J. Gene Med.
3, 188–194.
|
| |
| 173. |
Naldini, L., Blomer, U., Gallay, P., et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a
lentiviral vector [see comments]. Science
272, 263–267.
|
| |
| 174. |
Schnell, T., Foley, P., Wirth, M., Munch, I, and Uberla, K. (2000) Development of a self-inactivating, minimal lentivirus
vector based on simian immunodeficiency virus. Hum. Gene Ther.
11, 439–447.
|
| |
| 175. |
Olsen, J. C. (1998) Gene transfer vectors derived from equine infectious anemia virus. Gene Ther.
5, 1481–1487.
|
| |
| 176. |
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., and Trono, D. (1997) Multiply attenuated lentiviral vector achieves efficient
gene delivery in vivo. Nat. Biotechnol.
15, 871–875.
|
| |
| 177. |
Negre, D., Mangeot, P. E., Duisit, G., et al. (2000) Characterization of novel safe lentiviral vectors derived from simian
immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther.
7, 1613–1623.
|
| |
| 178. |
Johnston, J. and Power, C. (1999) Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency
virus: implications for vector development. J. Virol.
73, 2491–2498.
|
| |
| 179. |
Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M., and Mitrophanous, K. A. (2000) A Rev-independent human immunodeficiency
virus type 1 (HlV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol.
74, 4839–4852.
|
| |
| 180. |
Wagner, R., Graf, M., Bieler, K., et al. (2000) Rev-independent expression of synthetic gag-pol genes of human immunodeficiency
virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors [In Process Citation]. Hum. Gene Ther.
11, 2403–2413.
|
| |
| 181. |
Mautino, M. R., Keiser, N., and Morgan, R. A. (2000) Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive
transport element. Gene Ther.
7, 1421–1424.
|
| |
| 182. |
Markowitz, D., Goff, S., and Bank, A. (1988) A safe packaging line for gene transfer: separating viral genes on two different
plasmids. J. Virol.
62, 1120–1124.
|
| |
| 183. |
Miller, A. D., Garcia, J. V., von Suhr, N., Lynch, C. M., Wilson, C., and Eiden, M. V. (1991) Construction and properties
of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol.
65, 2220–2224.
|
| |
| 184. |
Cosset, F. L., Takeuchi, Y., Battini, J. L., Weiss, R. A., and Collins, M. K. (1995) High-titer packaging cells producing
recombinant retroviruses resistant to human serum. J. Virol.
69, 7430–7436.
|
| |
| 185. |
Pizzato, M., Merten, O. W., Blair, E. D., and Takeuchi, Y. (2001) Development of a suspension packaging cell line for production
of high titer, serum-resistant murine leukemia virus vectors. Gene Ther.
8, 737–745.
|
| |
| 186. |
Forestell, S. P., Dando, J. S., Chen, J., de Vries, P., Bohnlein, E., and Rigg, R. J. (1997) Novel retroviral packaging cell
lines: complementary tropisms and improved vector production for efficient gene transfer. Gene Ther.
4, 600–610.
|
| |
| 187. |
Rigg, R. J., Chen, J., Dando, J. S., Forestell, S. P., Plavec, I., and Bohnlein, E. (1996) A novel human amphotropic packaging
cell line: high titer, complement resistance, and improved safety. Virology
218, 290–295.
|
| |
| 188. |
Davis, J. L., Witt, R. M., Gross, P. R., et al. (1997) Retroviral particles produced from a stable human-derived packaging
cell line transduce target cells with very high efficiencies. Hum. Gene Ther.
8, 1459–1467.
|
| |
| 189. |
Swift, S., Lorens, J., Achacoso, P., and Nolan, G. P. (1999) Rapid production of retroviruses for efficient gene delivery
to mammalian cells using 293T cell-based systems. Curr. Protocols Immunol.
10, 14–29.
|
| |
| 190. |
Sheridan, P. L., Bodner, M., Lynn, A., et al. (2000) Generation of retroviral packaging and producer cell lines for large-scale
vector production and clinical application: improved safety and high titer. Mol. Ther.
2, 262–275.
|
| |
| 191. |
Ni, Y., Sun, S., Oparaocha, I., et al. (2005) Generation of a packaging cell line for prolonged large-scale production of
high-titer HIV-1-based lentiviral vector. J. Gene Med.
7, 818–834.
|
| |
| 192. |
Matsushita, T., Elliger, S., Elliger, C., et al. (1998) Adeno-associated virus vectors can be efficiently produced without
helper virus. Gene Ther.
5, 938–945.
|
| |
| 193. |
Grimm, D., Kern, A., Pawlita, M., Ferrari, F., Samulski, R., and Kleinschmidt, J. (1999) Titration of AAV-2 particles via
a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther.
6, 1322–1330.
|
| |
| 194. |
Collaco, R. F., Cao, X., and Trempe, J. P. (1999) A helper virus-free packaging system for recombinant adeno-associated virus
vectors. Gene
238, 397–405.
|
| |
| 195. |
Jenny, C., Toublancs, E., Danos, O., and Merten, O. W. (2006) Serum-free production of rAAV-2 using HeLa derived producer
cells. Cytotechnology
49, 11–23.
|
| |
| 196. |
Gao, G. P., Lu, F., Sanmiguel, J. C., et al. (2002) Rep/Cap gene amplification and high-yield production of AAV in an A549
cell line expressing Rep/Cap. Mol. Ther.
5, 644–649.
|
| |